Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma

References

• Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;2016(66):443–459.
   Google Scholar
• Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:10.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–2522.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199.
   PubMed Web of Science ®Google Scholar
• Andorsky DJ, Coleman M, Yacoub A, et al. MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL J Clin Oncol. 2020;38(15_suppl):8046.
   Web of Science ®Google Scholar
• Gopal AK, Krad BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017;35:3898–3905.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019;37:912–922.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2021;39:1609–1618.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Chavez JC, Sehgal A, et al. Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24) J Clin Oncol. . 2021;39(15_suppl):7515.
   Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–195.
   PubMed Web of Science ®Google Scholar
• Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46:176–181.
   PubMed Web of Science ®Google Scholar
• Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122:3165–3168.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8:22–33.
   PubMed Web of Science ®Google Scholar
• Mesin L, Ersching J, Victora GD. Germinal Center B Cell Dynamics. Immunity. 2016;45:471–482.
   PubMed Web of Science ®Google Scholar
• Mondello P, Fama A, Larson MC, et al. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J. 2021;11:130.
   PubMed Web of Science ®Google Scholar
• Malik A, Shoukier M, Garcia-Manero G, et al. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013;13:292–295.
   PubMed Web of Science ®Google Scholar
• Blum KA, Liu Z, Lucas DM, et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol. 2010;150:189–195.
   PubMed Web of Science ®Google Scholar
• Ogura M, Ando K, Suzuki T, et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014;165:768–776.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Kim WS, Bouabdallah R, et al. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017;102:903–909.
   PubMed Web of Science ®Google Scholar
• Mondello P, Derenzini E, Asgari Z, et al. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget. 2017;8(8):14017–14028.
   Google Scholar
• Younes A, Berdeja JG, Patel MR, et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016. DOI:https://doi.org/10.1016/S1470-2045(15)00584-7.
   Google Scholar
• Mondello P, Toska E, Teater M, et al. Targeting KDM5 demethylases counteracts KMT2D loss of function in diffuse large B-cell lymphoma AACR Advances in Malignant Lymphoma, Boston. 2018.
   Google Scholar
• Heward J, Konali L, D’Avola A, et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. 2021;138:370–381.
   PubMed Web of Science ®Google Scholar
• Mondello P, Tadros S, Teater M, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov 2020 CD-19-0116. DOI:https://doi.org/10.1158/2159-8290.CD-20-0773
   Google Scholar
• Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433–1442.
   PubMed Web of Science ®Google Scholar
• Caganova M, Carrisi C, Varano G, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 2013;123:5009–5022.
   PubMed Web of Science ®Google Scholar
• Béguelin W, Popovic R, Teater M, et al. EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell. 2013;23:677–692.
   PubMed Web of Science ®Google Scholar
• Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15:172–184.
   PubMed Web of Science ®Google Scholar
• Béguelin W, Popovic R, Teater M, et al. EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell. 2013;23:677–692.
   PubMed Web of Science ®Google Scholar
• Béguelin W, Rivas MA, Calvo Fernández MT, et al. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat Commun. 2017;8:8.
   PubMed Web of Science ®Google Scholar
• Caganova M, Carrisi C, Varano G, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 2013;123:5009–5022.
   PubMed Web of Science ®Google Scholar
• Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A. 2010;107:20980–20985.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Takata K, Béguelin W, et al. Molecular and genetic characterization of MHC deficiency identifies ezh2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9:546–563.
   PubMed Web of Science ®Google Scholar
• Otsuka Y, Nishikori M, Arima H, et al. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol. 2020;119:35–45.
   PubMed Web of Science ®Google Scholar
• Béguelin W, Teater M, Meydan C, et al. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell. 2020;37:655–673.e11.
   PubMed Web of Science ®Google Scholar
• Huet S, Xerri L, Tesson B, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017;7:e555.
   PubMed Web of Science ®Google Scholar
• Lockmer S, Ren W, Brodtkorb M, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188:259–267.
   PubMed Web of Science ®Google Scholar
• Jurinovic V, Passerini V, Oestergaard MZ, et al. Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy. Blood. 2019;134:122.
   Web of Science ®Google Scholar
• Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–1122.
   PubMed Web of Science ®Google Scholar
• Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128:1112–1120.
   PubMed Web of Science ®Google Scholar
• Xu B, On DM, Ma A, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13:842–854.
   PubMed Web of Science ®Google Scholar
• Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19:649–659.
   PubMed Web of Science ®Google Scholar
• Munakata W, Shirasugi Y, Tobinai K, et al. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci. 2021;112:1123–1131.
   PubMed Web of Science ®Google Scholar
• Izutsu K, Ando K, Nishikori M, et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021;112:3627–3635.
   PubMed Web of Science ®Google Scholar
• FDA granted accelerated approval to tazemetostat for follicular lymphoma | FDA. Available from: https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma
   Google Scholar
• Yap TA, Winter JN, Giulino-Roth L, et al. Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clin Cancer Res. 2019;25:7331–7339.
   PubMed Web of Science ®Google Scholar
• Xu B, On DM, Ma A, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125:346.
   PubMed Web of Science ®Google Scholar
• Ishitsuka K, Izutsu K, Maruyama D, et al. First-in-human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphomas. Hematol Oncol. 2021;39 Suppl 1:39.
   PubMedGoogle Scholar
• Sarkozy C, Morschhauser F, Dubois S, et al. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clin Cancer Res. 2020;26:3145–3153.
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarcheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527:249–253.
   PubMed Web of Science ®Google Scholar
• Palomba ML, Cartron G, Popplewell L, et al. Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large b-cell lymphoma: primary analysis of a phase 1b study. Hematol Oncol. 2019;37:517–519.
   Google Scholar
• Scholze H, Stephenson RE, Reynolds R, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4:5226–5231.
   PubMed Web of Science ®Google Scholar